These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 15334790)

  • 21. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB; Al Majali K; Bailey CJ; Betteridge DJ
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
    Ambavane V; Patil R; Ainapure SS
    J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
    [No Abstract]   [Full Text] [Related]  

  • 25. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
    Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
    Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state.
    Hohberg C; Forst T; Larbig M; Safinowski M; Diessel S; Hehenwarter S; Weber MM; Schöndorf T; Pfützner A
    Diabetes Care; 2008 May; 31(5):1021-5. PubMed ID: 18268067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of acarbose and simultaneous antacid therapy on blood glucose.
    Höpfner M; Durani B; Spengler M; Fölsch UR
    Arzneimittelforschung; 1997 Oct; 47(10):1108-11. PubMed ID: 9368703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
    Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
    Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
    Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
    Ogawa S; Takeuchi K; Ito S
    Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.